FGFR3 and Alzheimer disease: Comparatively, six-week Evo administration significantly reduced the level of AchE (p < 0.05; Table 1) and enhanced the levels of Ach and ChAT (p < 0.05; Table 1) in the serum, cerebral cortex, and hypothalamus of mice with AD-like behavior.